Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention-Health Disparities Subcommittee (HDS), 5115-5116 [2015-01766]
Download as PDF
<![CDATA[
5115
Federal Register / Vol. 80, No. 20 / Friday, January 30, 2015 / Notices
project period and one retrospective
data collection during the first year of
the three-year project period. The
retrospective data collection will
provide information about clients’
baseline characteristics prior to
participation in the model program
which is needed to compare outcomes
before and after program
implementation. Minor formatting
revisions are requested to the previously
approved data collection forms. Lastly,
CDC newly requests approval to
conduct key informant interviews with
program clinic and pharmacy staff in
order to evaluate the program processes
and to collect time and cost data which
will be used to estimate the cost of the
The data collection will allow CDC to
conduct continuous program
performance monitoring which includes
identification of barriers to program
implementation, solutions to those
barriers, and documentation of client
health outcomes. Performance
monitoring will allow the model
program to be adjusted, as needed, in
order to develop a final implementation
model that is self-sustaining and which
can be used to establish similar
collaborations in a variety of clinical
settings. Collection of cost data will
allow for the cost of the program to be
estimated.
There is no cost to participants other
than their time.
model program. The key informant
interviews and time and cost data are
additional data collections from the
original OMB approval.
Pharmacy, laboratory and medical
data will be collected through
abstraction of all participant clients’
pharmacy and medical records.
Pharmacy, laboratory and medical data
are needed to monitor retention in care,
adherence to therapy, viral load
suppression and other health outcomes.
Program specific data, such as the
number of MTM elements completed
per project site and time spent on
program activities, will be collected by
program. Qualitative data will be
gathered from program staff through inperson or telephone interviews.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Type of respondent
Form name
Clinic Data Manager ......
Pharmacist .....................
Clinic Data Manager ......
Clinic Data Manager ......
Clinic Data Manager ......
Pharmacist .....................
Key informants ...............
Clinic staff ......................
Pharmacy staff ...............
Project clinic characteristics form ........................
Project pharmacy characteristics form ................
Patient Demographic Information form ...............
Initial patient information form .............................
Quarterly patient information form .......................
Pharmacy record abstraction form ......................
Interviewer data collection worksheet .................
Clinic cost form ....................................................
Pharmacy cost form ............................................
10
10
10
10
10
10
60
20
20
3
3
100
100
400
400
2
2
2
30/60
30/60
5/60
1
30/60
30/60
30/60
10
10
15
15
83
1,000
2,000
2,000
60
400
400
Total ........................
..............................................................................
........................
........................
........................
5,973
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–01698 Filed 1–29–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Advisory Committee on Immunization
Practices: Notice of Charter
Amendment
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Advisory Committee on Immunization
Practices, Centers for Disease Control
and Prevention (CDC), Department of
Health and Human Services (HHS), has
amended their charter to reflect the
change in the filing date. The amended
filing date is January 13, 2015.
VerDate Sep<11>2014
18:50 Jan 29, 2015
Jkt 235001
For information, contact Dr. Larry
Pickering, Designated Federal Officer,
Advisory Committee on Immunization
Practices, HHS, CDC, 1600 Clifton Road
NE., Mailstop E05, Atlanta, Georgia
30333, telephone (404) 639–8562 or fax
(404) 639–8626.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2015–01767 Filed 1–29–15; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention—Health Disparities
Subcommittee (HDS)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned subcommittee:
Time and Date: 11:00 a.m.–12:30 p.m. EST,
February 26, 2015.
Place: This meeting will be held by
teleconference.
Status: This meeting is open to the public,
limited only by the availability of telephone
ports. The public is welcome to participate
during the public comment, which is
tentatively scheduled from 12:15 to 12:30
p.m. To participate in the teleconference,
please dial (866) 763–0273 Passcode:
6158968.
Purpose: The Subcommittee will provide
advice to the CDC Director through the ACD
on strategic and other health disparities and
E:\FR\FM\30JAN1.SGM
30JAN1
5116
Federal Register / Vol. 80, No. 20 / Friday, January 30, 2015 / Notices
health equity issues and provide guidance on
opportunities for CDC.
Matters for Discussion: The Health
Disparities Subcommittee members will
discuss progress toward implementation of
the Health Disparities Subcommittee
recommendations and discussion of the
Healthy People 2020 progress review on
social determinants of health and LGBT
health.
The agenda is subject to change as
priorities dictate.
Contact Person for More Information:
Leandris Liburd, Ph.D., M.P.H., M.A.,
Designated Federal Officer, Health
Disparities Subcommittee, Advisory
Committee to the Director, CDC, 1600 Clifton
Road NE., M/S K–77, Atlanta, Georgia 30333
Telephone (770) 488–8343, Email: LEL1@
cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
[FR Doc. 2015–01766 Filed 1–29–15; 8:45 am]
BILLING CODE 4163–18–P
The meeting announced below
concerns Occupational Safety and
Health Education and Research Centers
(ERC) PAR 10–217, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
Times and Dates:
6:00 p.m.–8:00 p.m., February 23, 2015
(Closed).
8:00 a.m.–6:00 p.m., February 24, 2015
(Closed).
8:00 a.m.–6:00 p.m., February 25, 2015
(Closed).
8:00 a.m.–6:00 p.m., February 26, 2015
(Closed).
Place: Renaissance Atlanta Midtown Hotel,
866 West Peachtree Street NW., Atlanta,
Georgia 30308, Telephone: (678) 412–2400.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Jkt 235001
George Bockosh, M.S., Scientific Review
Officer, National Institute for
Occupational Safety and Health
(NIOSH), CDC, 2400 Century Center
Parkway NE., 4th Floor, Mailstop E–74,
Atlanta, Georgia 30345, Telephone:
(412) 386–6465, GGB0@CDC.GOV and
Donald Blackman, Ph.D., Scientific
Review Officer, NIOSH, CDC, 2400
Century Center Parkway NE., 4th Floor,
Room 4204, Mailstop E–74, Atlanta,
Georgia 30345, Telephone: (404) 498–
6185, DYB7@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
18:50 Jan 29, 2015
FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2015–01817 Filed 1–29–15; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Matters for Discussion: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Occupational Safety and Health
Education and Research Centers (ERC) PAR
10–217.’’
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns ‘‘Comprehensive High-Impact
HIV Prevention Projects for CommunityBased Organizations’’, Funding
Opportunity Announcement (FOA)
PS15–1502, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Times and Dates: 9:00 a.m.–4:00 p.m. EST,
Panels 1–7; February 24, 2015 (Closed), 9:00
a.m.–4:00 p.m. EST, Panels 8–14; February
25, 2015 (Closed), 9:00 a.m.–4:00 p.m. EST,
Panels 15–19; February 26, 2015 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Matters for Discussion: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Comprehensive High-Impact
HIV Prevention Projects for CommunityBased Organizations’’ FOA PS15–1502.
Contact Person for More Information: Lisa
R. Williams, Public Health Analyst, CDC,
1600 Clifton Road NE., Mailstop E07,
Atlanta, Georgia 30333, Telephone: (404)
639–1877.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2015–01769 Filed 1–29–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices (ACIP)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following meeting of the
aforementioned committee.
Times and Dates:
8:00 a.m.–5:45 p.m., February 25, 2015.
8:00 a.m.–1:00 p.m., February 26, 2015.
Place: CDC, Tom Harkin Global
Communications Center, 1600 Clifton Road
NE., Building 19, Kent ‘‘Oz’’ Nelson
Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available.
Purpose: The committee is charged with
advising the Director, CDC, on the
appropriate use of immunizing agents. In
addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children (VFC) program, along
with schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines. Further, under
provisions of the Affordable Care Act, at
section 2713 of the Public Health Service
Act, immunization recommendations of the
ACIP that have been adopted by the Director
of the Centers for Disease Control and
Prevention must be covered by applicable
health plans.
Matters for discussion: The agenda will
include discussions on: General
recommendations; meningococcal vaccines;
human papillomavirus vaccines; influenza;
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 80, Number 20 (Friday, January 30, 2015)]
[Notices]
[Pages 5115-5116]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01766]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee to the Director (ACD), Centers for Disease
Control and Prevention--Health Disparities Subcommittee (HDS)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned
subcommittee:
Time and Date: 11:00 a.m.-12:30 p.m. EST, February 26, 2015.
Place: This meeting will be held by teleconference.
Status: This meeting is open to the public, limited only by the
availability of telephone ports. The public is welcome to
participate during the public comment, which is tentatively
scheduled from 12:15 to 12:30 p.m. To participate in the
teleconference, please dial (866) 763-0273 Passcode: 6158968.
Purpose: The Subcommittee will provide advice to the CDC
Director through the ACD on strategic and other health disparities
and
[[Page 5116]]
health equity issues and provide guidance on opportunities for CDC.
Matters for Discussion: The Health Disparities Subcommittee
members will discuss progress toward implementation of the Health
Disparities Subcommittee recommendations and discussion of the
Healthy People 2020 progress review on social determinants of health
and LGBT health.
The agenda is subject to change as priorities dictate.
Contact Person for More Information: Leandris Liburd, Ph.D.,
M.P.H., M.A., Designated Federal Officer, Health Disparities
Subcommittee, Advisory Committee to the Director, CDC, 1600 Clifton
Road NE., M/S K-77, Atlanta, Georgia 30333 Telephone (770) 488-8343,
Email: LEL1@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention (CDC).
[FR Doc. 2015-01766 Filed 1-29-15; 8:45 am]
BILLING CODE 4163-18-P
